By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen Therapeutics 

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students 7/17/2013 8:02:08 AM
Janssen Therapeutics Release: Survey of Participants from Landmark GRACE Trial Provides Patients' Perspectives From an HIV Clinical Study 5/31/2013 9:18:33 AM
Janssen Therapeutics LINCC™ Program Continues Its Commitment to Underserved Populations With Charitable Contributions to 16 HIV/AIDS Organizations Across the U.S. 4/24/2013 10:20:28 AM
Janssen Therapeutics Release: FDA Approves Prescribing Information Update for EDURANT® (Rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients 12/11/2012 9:09:14 AM
Janssen Therapeutics's Prezista 800 Mg Tablet Receives FDA Approval 11/12/2012 7:07:49 AM
Janssen Therapeutics Release: Award-Winning Documentary, The Other City, Returns to Washington, D.C. for AIDS 2012 7/24/2012 11:07:01 AM
Janssen Therapeutics Release: FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 5/29/2012 11:06:43 AM
Janssen Therapeutics Release: Watching, Reading and Listening: A New Way to Interact with Patient Information 4/25/2012 9:12:21 AM
Janssen Therapeutics Establishes Point Scholarship for LGBT Students 4/12/2012 2:43:45 PM
FDA Approves Janssen Therapeutics INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients With HIV-1, Following Priority Review 3/27/2012 7:23:11 AM
12
//-->